title: Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
abstract: There is a critical need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis. Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions. Blockade of the JAK1/JAK3-STAT pathway with a small molecule was anticipated to provide therapeutic immunosuppression/immunomodulation. The Pfizer compound library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by CP-352,664 (2a). Synthetic analogues of 2a were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay. Select compounds were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis. Optimization within this chemical series led to identification of CP-690,550 1, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.
authors.affiliation: Groton Laboratories, Pfizer Global Research & Development, Groton, Connecticut 06340, USA. mark.e.flanagan@pfizer.com
authors.forename: Mark E
authors.initials: ME
authors.lastname: Flanagan
authors.forename: Todd A
authors.initials: TA
authors.lastname: Blumenkopf
authors.forename: William H
authors.initials: WH
authors.lastname: Brissette
authors.forename: Matthew F
authors.initials: MF
authors.lastname: Brown
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Casavant
authors.forename: Chang
authors.initials: C
authors.lastname: Shang-Poa
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Doty
authors.forename: Eileen A
authors.initials: EA
authors.lastname: Elliott
authors.forename: Michael B
authors.initials: MB
authors.lastname: Fisher
authors.forename: Michael
authors.initials: M
authors.lastname: Hines
authors.forename: Craig
authors.initials: C
authors.lastname: Kent
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Kudlacz
authors.forename: Brett M
authors.initials: BM
authors.lastname: Lillie
authors.forename: Kelly S
authors.initials: KS
authors.lastname: Magnuson
authors.forename: Sandra P
authors.initials: SP
authors.lastname: McCurdy
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Munchhof
authors.forename: Bret D
authors.initials: BD
authors.lastname: Perry
authors.forename: Perry S
authors.initials: PS
authors.lastname: Sawyer
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Strelevitz
authors.forename: Chakrapani
authors.initials: C
authors.lastname: Subramanyam
authors.forename: Jianmin
authors.initials: J
authors.lastname: Sun
authors.forename: David A
authors.initials: DA
authors.lastname: Whipple
authors.forename: Paul S
authors.initials: PS
authors.lastname: Changelian
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy*; D001798:Blood Proteins / Q000378:metabolism; D018938:Caco-2 Cells; D045744:Cell Line, Tumor; D002463:Cell Membrane Permeability; D049109:Cell Proliferation / Q000187:drug effects; D000081005:Cyclohexane Monoterpenes; D004285:Dogs; D005260:Female; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D066298:In Vitro Techniques; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D008213:Lymphocyte Activation / Q000187:drug effects; D008252:Macaca fascicularis; D008297:Male; D008958:Models, Molecular; D039821:Monoterpenes / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology; D010880:Piperidines / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology; D011485:Protein Binding; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D011758:Pyrroles / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D014018:Tissue Distribution
chemical_list: D001798:Blood Proteins; D000081005:Cyclohexane Monoterpenes; D039821:Monoterpenes; D010880:Piperidines; D011743:Pyrimidines; D011758:Pyrroles; C006923:carvone; C479163:tofacitinib; D053612:Janus Kinases